Medtronic's VenaSeal Data Lands 88% Healing Rate as MiniMed Swap Clock Runs Down
Published on 10/07/2026 at 14:41 | Editorial boerse-global.de
Medtronic is squeezing two very different storylines into the same trading week. On one side sits a fresh set of long-term clinical results for its VenaSeal system; on the other, a three-day price-discovery window that closes today and will fix the terms of the company's diabetes spinoff.
The stock was quoted at EUR 78.50 on Wednesday, up 1.5%, as investors weighed the medical data against the mechanics of the MiniMed exchange offer.
Two years, 125 patients, one clear result
The centerpiece of the clinical update is the 24-month readout from the VenaSeal Spectrum study, which enrolled 125 patients suffering from active venous leg ulcers. After two years of follow-up, the ulcer healing rate reached 88.1%. The same dataset showed an anatomical closure rate of 78% in the treated veins at the 24-month mark.
That kind of long-horizon evidence matters to both physicians and payers, because it demonstrates that the minimally invasive procedure holds up well beyond the acute treatment phase. For Medtronic, it is another brick in the wall of clinical proof supporting its vascular franchise.
The numbers arrive against a backdrop of heavy spending. In its accountability report for fiscal 2026, Medtronic disclosed research and development outlays of USD 2.9 billion, and the company says its therapies have now reached more than 82 million patients worldwide.
Should investors sell immediately? Or is it worth buying Medtronic?
Wall Street warms up
Analysts have taken note. RBC Capital reaffirmed its buy rating on Medtronic in a note dated October 1, according to media reports, with a price target of USD 118.00.
That endorsement sits alongside a broader shift in sentiment toward the medtech sector. Barclays initiated coverage on October 6 with an Equal Weight rating and a USD 95 target, arguing that recent weakness across medical technology has opened entry points into quality names at attractive multiples. The bank expects a fundamental stabilization from 2027 onward. Citi, for its part, reiterated its buy call on October 5 with a USD 110 target.
The exchange offer enters its final hours
While the clinical news was landing, Medtronic shareholders were working through a more immediate arithmetic problem. Wednesday's close marks the end of the three-day window used to calculate the volume-weighted average price — the VWAP drawn from the trading sessions of October 5 through October 7 — that will determine the final exchange ratio for swapping Medtronic common stock into MiniMed Group shares.
The offer itself expires Friday, October 9, at midnight New York time, unless Medtronic extends the deadline or closes the offer early. Under the terms filed with the U.S. Securities and Exchange Commission, the deal carries a 7% discount to MiniMed's market value, subject to a cap. Medtronic is offering up to 225,361,295 newly issued MiniMed shares in exchange for its own common stock.
For existing holders, the decision is a strategic fork in the road: keep a stake in the diversified medtech group, or bet purely on the diabetes business.
Enough incentive?
The open question over the coming sessions is whether that 7% discount is generous enough to draw sufficient participation. Media reports have flagged growing doubts about whether the financial sweetener will appeal to a majority of investors, and a stalled exchange could complicate the separation Medtronic is aiming for.
The market has already registered some skepticism. Over the past 30 days, the shares have shed 5.8%. If too few holders tender, Medtronic may need to sweeten the terms, extend the deadline, or pursue alternative routes to place the remaining MiniMed stock — a detour that would delay the hoped-for portfolio cleanup and tie up management attention.
Medtronic at a turning point? This analysis reveals what investors need to know now.
Regulatory tailwinds, with a lag
Operationally, Medtronic has been stacking up wins. On September 30, the company announced FDA clearance and CE marking for its Affera Prism-2 mapping software, along with CE approval for the PulseSelect ProxBox adapter. Roughly a week earlier, the American Medical Association bolstered reimbursement prospects by granting new Category I codes for the Altaviva and Symplicity Spyral systems starting January 2028; the stock has gained 1.5% since then.
Those improved billing codes, however, only take effect in 2028, meaning no direct revenue bump from the change is on the near-term horizon.
What to watch
Defending the recent trading range is the key technical question. As long as the shares hold their latest interim low, the path remains open for a re-rating once the spinoff is complete. A weak take-up — well short of the roughly 225.3 million-share maximum — would risk extending the recent slide.
The next hard catalyst is already on the calendar. The acceptance period for the MiniMed offer ends in New York in the early hours of Saturday, October 10. The official announcement of the final exchange result should set the direction for the stock at the start of the coming trading week.
Ad
Medtronic Stock: New Analysis - 7 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
